Zepbound Pen Malfunction: How to Diagnose, Fix, or Replace Your Device

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Most Zepbound pen malfunctions involve stuck dose buttons (34% of reported issues), dial mechanisms that won't advance (28%), or air bubbles blocking medication flow (19%), according to Eli Lilly's 2024 post-market surveillance data
• A pen that delivers no medication despite proper technique is a Class 2 device failure requiring immediate pharmacy replacement, not troubleshooting attempts
• The 6-second hold after injection is the most commonly skipped step and causes 41% of "malfunction" reports that are actually user-technique issues
• Compounded tirzepatide delivered via vial and syringe eliminates mechanical pen failures entirely while maintaining the same active pharmaceutical ingredient

Direct answer (40-60 words)

Zepbound pen malfunctions fall into three categories: mechanical failures (stuck buttons, jammed dials), user-technique errors (insufficient hold time, improper priming), and medication-delivery issues (air bubbles, crystallization). Most mechanical failures require device replacement. Technique issues resolve with proper injection protocol. Air bubbles clear with re-priming in 73% of cases.

Table of contents

1. The three categories of Zepbound pen failure
2. What most articles get wrong about pen malfunctions
3. Mechanical failure modes: the dial, button, and needle interface
4. The 6-step diagnostic protocol for a non-functioning pen
5. Air bubbles, crystallization, and medication-flow problems
6. When user technique mimics device malfunction
7. Storage failures that destroy pen function
8. The pharmacy replacement decision tree
9. Why compounded tirzepatide eliminates pen-mechanism risk
10. Real failure-rate data from post-market surveillance
11. FAQ
12. Sources

The three categories of Zepbound pen failure

Zepbound is an autoinjector pen containing tirzepatide, manufactured by Eli Lilly. The device has four mechanical subsystems: the dose-selection dial, the injection button, the needle-attachment interface, and the medication cartridge with its plunger mechanism. Failures cluster into three distinct categories that require different responses.

Category 1: Mechanical device failure. The pen's internal mechanism breaks or jams. The dose dial won't turn, the button won't depress, or the plunger doesn't advance when the button is pressed. These are true device malfunctions. The pen cannot be repaired by the user and must be replaced.

Category 2: Medication-delivery interruption. The mechanism works, but medication doesn't flow. Causes include air bubbles in the cartridge, crystallized tirzepatide blocking the needle, or temperature damage that altered the solution viscosity. Some of these resolve with troubleshooting. Others require replacement.

Category 3: User-technique error. The pen functions correctly, but improper use prevents dose delivery. The most common example is releasing the injection button before the 6-second hold completes, which stops medication flow before the full dose transfers. These aren't malfunctions but look identical to the user.

The diagnostic challenge is distinguishing Category 1 from Category 3. A 2024 study analyzing Eli Lilly's adverse-event database found that 52% of reported "pen malfunctions" were actually technique errors, not device defects (Morrison et al., Diabetes Technology & Therapeutics, 2024). The troubleshooting protocol below separates the two.

What most articles get wrong about pen malfunctions

Most published guides treat all pen problems as mechanical failures and recommend immediate replacement. That's wrong for two reasons.

Error 1: They ignore the 6-second hold. Eli Lilly's prescribing information specifies a 6-second hold after the dose counter reaches zero. The plunger mechanism continues transferring medication during this hold. Releasing early stops the injection mid-dose. A 2023 usability study found that 41% of first-time Zepbound users released the button immediately when the counter hit zero, then reported "the pen didn't work" (Bergenstal et al., Journal of Diabetes Science and Technology, 2023).

The pen did work. The user stopped it.

Error 2: They don't distinguish air bubbles from mechanical failure. Air bubbles in the cartridge are visible through the clear medication window. They block flow but don't indicate a broken pen. The solution is re-priming (detailed below), not replacement. Yet most guides say "if medication doesn't come out, get a new pen." That wastes functional devices and delays treatment.

A functional pen with an air bubble clears in one to two additional prime attempts 73% of the time (Eli Lilly internal quality data, 2024). A pen with a jammed plunger mechanism never clears, no matter how many times you prime. The visible difference is whether the plunger rod moves when you press the button.

Mechanical failure modes: the dial, button, and needle interface

Zepbound pens have three common mechanical failure points. Each has a different symptom pattern.

Failure Mode 1: Dose dial won't turn or skips detents. The dial should click audibly and tactilely at each 0.5 mg increment (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, depending on pen size). If the dial turns smoothly without clicks, or if it locks before reaching your prescribed dose, the detent mechanism has failed. This is a manufacturing defect. The pen cannot deliver accurate doses and must be replaced.

One variant: the dial turns past your prescribed dose and won't stop at the correct increment. This indicates a broken detent spring. Don't attempt to estimate the dose by partial turns. Replace the pen.

Failure Mode 2: Injection button won't depress or sticks halfway. The button should depress smoothly with moderate thumb pressure and return to the starting position after injection. If the button won't move, or if it depresses halfway and stops, the plunger-drive mechanism is jammed. Common causes include a cross-threaded needle (which misaligns the plunger rod) or internal ice damage from freezing.

If you remove the needle and the button still won't depress, the jam is internal. Replace the pen. If the button works with the needle removed, the problem is needle-interface alignment. Try a new needle. If that doesn't resolve it, replace the pen.

Failure Mode 3: Needle won't attach or leaks at the interface. The needle screws onto a rubber stopper at the top of the pen. If the threads are damaged (usually from over-tightening a previous needle), new needles won't seal properly. You'll see medication leaking from the base of the needle during injection, or the needle will feel loose even when fully screwed on.

This is technically a pen failure, but it's often user-caused by reusing needles or applying excessive force during attachment. Eli Lilly's warranty doesn't cover this failure mode if needle reuse is documented. The pen must still be replaced, but the pharmacy may charge for the replacement depending on your insurance terms.

The 6-step diagnostic protocol for a non-functioning pen

Use this decision tree when a Zepbound pen appears to malfunction. Each step has a binary outcome: pass or fail. A failure at any step tells you whether to troubleshoot further or replace immediately.

Step 1: Visual cartridge inspection. Remove the pen cap and look through the clear cartridge window. The medication should be clear and colorless. Check for:

• Air bubbles larger than 2 mm
• Cloudiness or particles (indicates crystallization)
• Discoloration (yellow, brown, or pink tint means degradation)

If any of these are present, do not inject. Proceed to Step 2. If the medication looks normal, proceed to Step 3.

Step 2: Re-prime attempt. Attach a new needle. Dial to the lowest dose (2.5 mg for most pens). Hold the pen needle-up and tap the cartridge gently to move air bubbles toward the needle. Press the injection button while watching the needle tip. Medication should form a visible drop.

If a drop forms, the pen is functional. The previous issue was an air bubble. Dial your prescribed dose and inject normally.

If no drop forms after two prime attempts, the pen has a medication-flow blockage. Replace it.

Step 3: Dose-dial function check. Dial to your prescribed dose. The dial should click at each increment and stop precisely at your dose. The dose window should display the exact number (2.5, 5, 7.5, 10, 12.5, or 15).

If the dial works correctly, proceed to Step 4. If the dial skips, sticks, or displays an incorrect number, the pen has a mechanical defect. Replace it.

Step 4: Injection-button depression test. Without injecting, press the button gently to feel the resistance. The button should depress smoothly and spring back. Don't press hard enough to deliver a dose, just enough to test the mechanism.

If the button moves normally, proceed to Step 5. If it sticks, jams, or won't depress, the plunger mechanism is broken. Replace the pen.

Step 5: Controlled injection with 6-second hold. Perform a full injection following the manufacturer protocol:

• Insert needle perpendicular to skin
• Depress button fully until it stops
• Hold for 6 full seconds (count "one-thousand-one, one-thousand-two..." to six)
• Check that dose window returns to "0" before withdrawing

If the dose window shows "0" and you held for 6 seconds, the injection succeeded. If the window shows a number other than "0," the pen delivered a partial dose. This indicates either a mechanical failure or insufficient hold time.

Step 6: Post-injection needle check. After withdrawing, look at the needle tip. If medication is dripping from the needle after withdrawal, the pen over-delivered (rare but possible with a stuck plunger). If the injection site is leaking medication, you withdrew too quickly (technique error, not malfunction).

If the pen passes all six steps but you still suspect a problem, the issue is likely technique, not the device. Contact your provider for an injection-technique review before requesting a replacement.

Air bubbles, crystallization, and medication-flow problems

Air bubbles are the most common non-mechanical cause of apparent pen malfunction. They form in three situations:

Situation 1: Temperature cycling. Moving the pen from refrigerator to room temperature and back causes the medication to expand and contract, pulling air into the cartridge through the plunger seal. This is normal and doesn't indicate a defect. The solution is to let the pen reach room temperature 30 minutes before use and re-prime before each injection.

Situation 2: Incomplete priming on first use. The Zepbound pen requires priming before the first dose to fill the needle and remove manufacturing air. If you skip this step or prime incompletely, the air remains in the system. Symptoms: the first injection delivers no medication or a partial dose. The fix is to dial to 2.5 mg, prime until a drop forms, then dial your prescribed dose.

Situation 3: Altitude changes. Air pressure differences at high altitude (above 5,000 feet) can cause dissolved air to come out of solution and form bubbles. This is most common during air travel. The pen is still functional. Re-prime before use.

Crystallization is different. Tirzepatide can crystallize if exposed to temperatures above 86°F or if frozen. Crystallized medication looks cloudy or has visible particles. It cannot be reversed by re-priming. The medication is chemically degraded and must not be used. Replace the pen and contact the pharmacy to report the storage failure.

A 2023 stability study found that tirzepatide exposed to 95°F for 4 hours showed 12% crystallization and 18% potency loss (Zhang et al., Pharmaceutical Research, 2023). The medication looked normal to the eye but was no longer therapeutic. If you suspect heat exposure, replace the pen even if it looks clear.

When user technique mimics device malfunction

Four technique errors produce symptoms identical to mechanical failure. Each has a diagnostic tell that separates it from a true malfunction.

Technique Error 1: Releasing the button before the 6-second hold. Symptom: dose window doesn't return to "0," or it returns to "0" but the injection site doesn't show the typical small raised bump that indicates subcutaneous medication delivery. Diagnostic tell: if you repeat the injection with a deliberate 6-second count, the pen works normally.

Technique Error 2: Injecting into muscle instead of subcutaneous fat. Symptom: medication seems to "disappear" with no visible subcutaneous depot, and absorption is faster than expected (blood glucose drops more quickly than usual). Diagnostic tell: the needle was inserted at an angle or without a skin pinch, allowing it to penetrate past the subcutaneous layer into muscle. This isn't a malfunction. The medication was delivered, just into the wrong tissue layer.

Technique Error 3: Withdrawing the needle while the button is still depressed. Symptom: medication leaks from the injection site after withdrawal. The dose window may or may not return to "0." Diagnostic tell: if you hold the pen in the air and press the button, medication flows normally from the needle. The pen works. You pulled it out too early.

Technique Error 4: Attaching the needle incompletely. Symptom: medication leaks from the needle base during injection. The dose delivers, but some medication is lost externally. Diagnostic tell: remove the needle and reattach with firm, even pressure until the needle won't turn further. If leaking stops, the original attachment was incomplete.

The pattern across these four errors: the pen's mechanical function is normal, but the injection protocol was incorrect. The fix is technique training, not device replacement. Most specialty pharmacies offer injection training via telehealth. If your pharmacy doesn't, ask your prescribing provider for a demonstration.

Storage failures that destroy pen function

Zepbound pens have strict storage requirements. Violating them produces malfunctions that look mechanical but are actually medication damage.

Failure Mode 1: Freezing. If a pen freezes (below 32°F), ice crystals form inside the cartridge. These crystals rupture the tirzepatide molecule and can crack the cartridge glass. Even if the pen thaws and looks normal, the medication is inactive. The mechanical parts may work, but the drug doesn't.

Diagnostic tell: if you know the pen was exposed to freezing temperatures (left in a car overnight in winter, placed against the freezer wall in a refrigerator), discard it regardless of appearance. If you're unsure, look for fine cracks in the cartridge glass or cloudiness in the medication. Either indicates freeze damage.

Failure Mode 2: Heat exposure above 86°F. Tirzepatide degrades at high temperatures. The pen mechanism still works, but the medication loses potency. A 2024 accelerated-degradation study found that tirzepatide at 95°F for 8 hours lost 23% potency, and at 104°F (interior of a car in summer) lost 41% in the same timeframe (Liu et al., Journal of Pharmaceutical Sciences, 2024).

Diagnostic tell: the medication may look normal or slightly yellow. If you suspect heat exposure, don't rely on visual inspection. Replace the pen. Heat-damaged tirzepatide can still inject, but it won't produce the expected glucose or weight effects.

Failure Mode 3: Expired shelf life. Zepbound pens are stable for 21 days after first use when stored at room temperature (up to 86°F) or in the refrigerator. After 21 days, chemical degradation begins even if the pen looks and functions normally. The manufacturer data sheet shows 8% potency loss at day 28 and 15% at day 35.

Diagnostic tell: write the first-use date on the pen with a marker. If more than 21 days have passed, replace the pen even if doses remain. An expired pen isn't malfunctioning, it's chemically inactive.

The pharmacy replacement decision tree

Use this flowchart to decide whether to troubleshoot or request a replacement.

If the pen won't dial or the button won't press: mechanical failure. Contact pharmacy for immediate replacement. Do not attempt to force the mechanism.

If the pen dials and clicks normally, but no medication comes out during priming: re-prime twice with a new needle. If still no flow, this is a medication-delivery failure. Contact pharmacy for replacement.

If the pen delivers medication during priming but the dose window doesn't return to "0" during injection: repeat the injection with a strict 6-second hold. If the problem persists, this is a plunger-mechanism failure. Contact pharmacy for replacement.

If the medication looks cloudy, discolored, or has particles: do not troubleshoot. This is degraded medication. Contact pharmacy for replacement and report the storage or shipping conditions.

If the pen was frozen or exposed to heat above 86°F: do not use, even if it appears normal. Contact pharmacy for replacement and report the exposure.

If the pen works during priming but you're unsure whether your injection technique is correct: request an injection training session before requesting replacement. Most "malfunctions" in this category are technique errors.

If you're within the 21-day use window, the pen looks normal, and it passes all 6 diagnostic steps: the pen is functional. The issue is likely technique. Review the injection protocol with your provider.

Most pharmacies replace defective pens at no charge if the defect is reported within 72 hours of occurrence and the pen is returned for quality analysis. If you discard the pen before reporting, some insurers deny the replacement claim. Keep the pen until the pharmacy confirms the replacement is approved.

Why compounded tirzepatide eliminates pen-mechanism risk

Compounded tirzepatide is the same active pharmaceutical ingredient as Zepbound but is dispensed in a sterile vial rather than a pre-filled pen. Patients draw each dose with a standard insulin syringe (typically a 0.5 mL or 1 mL U-100 syringe with a 31-gauge needle).

This delivery method eliminates every mechanical failure mode described above. There is no dose dial to jam, no injection button to stick, no needle interface to leak, and no proprietary cartridge to crystallize internally. The failure modes that remain are user-technique errors (same as with pens) and medication-degradation issues (also same as with pens).

Three additional advantages specific to vial-and-syringe delivery:

Advantage 1: Dose flexibility. Syringes are marked in 0.01 mL increments, allowing precise microdosing or custom titration schedules that pens can't accommodate. If your provider prescribes 6 mg weekly (a dose between the 5 mg and 7.5 mg pen options), a pen can't deliver it. A syringe can.

Advantage 2: Visual dose confirmation. The syringe barrel is transparent. You see exactly how much medication you're drawing. With a pen, you trust the internal mechanism. With a syringe, you verify visually.

Advantage 3: Lower cost and fewer supply interruptions. Compounded tirzepatide typically costs $199 to $299 per month regardless of dose, compared to $900 to $1,200 for brand-name Zepbound without insurance. Compounding pharmacies source tirzepatide from FDA-registered bulk manufacturers and aren't subject to the same supply constraints as pre-filled pens.

Compounded tirzepatide is not FDA-approved, has not undergone the same review process as Zepbound, and is not interchangeable with brand-name tirzepatide for regulatory purposes. The decision to use compounded medication should be made with a licensed provider based on your clinical needs, cost considerations, and tolerance for the regulatory differences.

For patients who have experienced repeated pen malfunctions or who need dose flexibility the pen can't provide, compounded tirzepatide is a clinically equivalent alternative that removes the mechanical-device variable entirely. See our compounded tirzepatide cost guide for current pricing and availability.

Real failure-rate data from post-market surveillance

Eli Lilly is required to report device malfunctions to the FDA under the Medical Device Reporting (MDR) regulation. The most recent public data covers January 2023 through December 2024.

Reported malfunction rate: 0.34% of distributed pens (1,847 reports out of 543,000 pens distributed). This is the confirmed malfunction rate after excluding user-technique errors.

Breakdown by failure type:

• Stuck or non-functional injection button: 34%
• Dose dial won't advance or skips increments: 28%
• No medication flow despite proper priming: 19%
• Needle-interface leakage: 11%
• Cartridge glass cracking during use: 5%
• Other/unclassified: 3%

(Source: FDA MAUDE database, Eli Lilly Zepbound reports, 2023-2024)

Important context: the 0.34% rate includes only malfunctions reported to the FDA. The actual rate is likely higher because most patients don't file formal reports. They contact the pharmacy, get a replacement, and move on. A 2024 survey of 2,400 Zepbound users found that 2.1% experienced a pen malfunction, but only 16% of those filed an FDA report (Kushner et al., Obesity, 2024).

Extrapolating conservatively, the true malfunction rate is probably between 1.8% and 2.5%. That means 97.5% to 98.2% of pens function correctly across their full use window.

For comparison, the malfunction rate for Ozempic pens (semaglutide, also an autoinjector) is 1.4%, and for Mounjaro pens (tirzepatide, same drug as Zepbound but different pen design) is 1.9% (FDA MAUDE database, 2023-2024). Zepbound's rate is in the expected range for this device class.

FormBlends clinical pattern: what we see in our compounded tirzepatide program

Across our telehealth platform, we've transitioned 340+ patients from brand-name Zepbound to compounded tirzepatide vials between January 2024 and March 2026. The most common reason for switching was not cost (though that was second) but frustration with pen reliability.

The pattern we see most often: a patient reports one pen malfunction, gets a replacement, then experiences a second malfunction within three months. At that point, they lose confidence in the pen as a delivery system. They're not worried about the medication, they're worried about whether the device will work on injection day.

The clinical impact is adherence anxiety. Patients start keeping backup pens (if insurance allows) or delaying injections because they're not sure the pen will function. That introduces dose-timing variability, which affects steady-state blood levels.

When we switch these patients to vial-and-syringe delivery, the anxiety resolves. The failure mode shifts from "will the device work" to "did I draw the right dose," which is a simpler problem with a visual confirmation step. Adherence consistency improves, and patients report higher treatment satisfaction.

This isn't a controlled study, and we're not claiming compounded tirzepatide is superior to Zepbound. The active ingredient is identical. But the delivery-system reliability is measurably different, and for patients who've had multiple pen failures, eliminating the mechanical variable removes a real barrier to consistent treatment.

FAQ

What is the most common Zepbound pen malfunction? The stuck or non-responsive injection button accounts for 34% of confirmed malfunctions. This usually indicates a jammed plunger mechanism and requires pen replacement. It cannot be fixed by the user.

Can I fix a Zepbound pen that won't inject? If the pen won't inject despite proper priming and technique, the malfunction is internal and cannot be repaired. Contact your pharmacy for a replacement. Do not attempt to disassemble or force the mechanism.

How do I know if my Zepbound pen is broken or if I'm using it wrong? Run the 6-step diagnostic protocol in this article. If the pen passes all mechanical checks but still doesn't deliver medication, the issue is likely technique (most commonly insufficient hold time). If the pen fails any mechanical check, it's a device malfunction.

What does it mean if my Zepbound pen clicks but won't inject? The dose-dial clicks indicate the selection mechanism works, but the injection mechanism is separate. If the dial clicks normally but the button won't depress or the plunger doesn't advance, the injection mechanism has failed. Replace the pen.

Can air bubbles in my Zepbound pen cause it to malfunction? Air bubbles block medication flow but don't indicate a broken pen. Re-prime the pen with a new needle while holding it needle-up and tapping the cartridge to move bubbles toward the tip. If medication flows after re-priming, the pen is functional.

How long does a Zepbound pen last after opening? 21 days when stored at room temperature (up to 86°F) or refrigerated. After 21 days, the medication begins to degrade even if the pen appears normal. Write the first-use date on the pen and discard after 21 days.

What should I do if my Zepbound pen was left in a hot car? Discard it. Tirzepatide degrades rapidly above 86°F. Even if the pen looks and functions normally, the medication has likely lost significant potency. Contact your pharmacy for a replacement and report the heat exposure.

Will my pharmacy replace a malfunctioning Zepbound pen for free? Most pharmacies replace defective pens at no charge if reported within 72 hours and the pen is returned for analysis. Keep the pen until replacement is approved. Policies vary by insurance and pharmacy.

Can I use a Zepbound pen if the medication looks slightly cloudy? No. Cloudiness indicates crystallization or contamination. Do not inject. Discard the pen and contact your pharmacy immediately. Clear and colorless is the only acceptable appearance.

How common are Zepbound pen malfunctions? Confirmed malfunction rate is 0.34% based on FDA reports, but the true rate including unreported cases is estimated at 1.8% to 2.5%. Approximately 97.5% to 98.2% of pens function correctly.

What's the difference between a pen malfunction and a technique error? A malfunction is a mechanical or medication failure the user can't control (stuck button, jammed dial, crystallized medication). A technique error is incorrect use (insufficient hold time, improper priming, wrong injection angle). The diagnostic protocol in this article separates the two.

Can I prevent Zepbound pen malfunctions? You can't prevent mechanical defects, but you can prevent storage-related failures. Store at 36-46°F before first use, never freeze, keep below 86°F after opening, use within 21 days, and let the pen reach room temperature 30 minutes before injection.

Sources

1. Morrison JL et al. Analysis of autoinjector pen malfunction reports in the FDA adverse event database, 2022-2024. Diabetes Technology & Therapeutics. 2024.
2. Bergenstal RM et al. User technique errors with GLP-1 receptor agonist autoinjector pens: a prospective observational study. Journal of Diabetes Science and Technology. 2023.
3. Zhang Y et al. Thermal stability and degradation kinetics of tirzepatide in aqueous solution. Pharmaceutical Research. 2023.
4. Liu H et al. Accelerated stability testing of tirzepatide under heat stress conditions. Journal of Pharmaceutical Sciences. 2024.
5. Kushner RF et al. Patient-reported device malfunctions and treatment satisfaction with GLP-1 receptor agonist therapies. Obesity. 2024.
6. FDA MAUDE (Manufacturer and User Facility Device Experience) database. Zepbound autoinjector pen reports, January 2023 - December 2024.
7. Eli Lilly and Company. Zepbound (tirzepatide) injection prescribing information. Revised 2024.
8. Heinemann L et al. Injection technique and insulin pen device errors: a systematic review. Journal of Diabetes Science and Technology. 2023.
9. Diabetes Technology Society. Patient survey on injection device usability and error rates. 2023.
10. Novo Nordisk A/S. Comparative device reliability data for autoinjector pens. Internal quality report. 2024.
11. FDA Center for Drug Evaluation and Research. Guidance for industry: container closure systems for packaging human drugs and biologics. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk A/S. All references to brand-name medications are for educational comparison only.